[go: up one dir, main page]

WO2002062369A3 - Combinaisons d'uroguanyline et d'inhibiteur de cyclooxygenase-2 pour l'inhibition du cancer de l'intestin - Google Patents

Combinaisons d'uroguanyline et d'inhibiteur de cyclooxygenase-2 pour l'inhibition du cancer de l'intestin Download PDF

Info

Publication number
WO2002062369A3
WO2002062369A3 PCT/US2002/003201 US0203201W WO02062369A3 WO 2002062369 A3 WO2002062369 A3 WO 2002062369A3 US 0203201 W US0203201 W US 0203201W WO 02062369 A3 WO02062369 A3 WO 02062369A3
Authority
WO
WIPO (PCT)
Prior art keywords
uroguanylin
inhibition
cyclooxygenase
inhibitor
intestinal cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/003201
Other languages
English (en)
Other versions
WO2002062369A2 (fr
Inventor
Jaime L Masferrer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Priority to CA002435835A priority Critical patent/CA2435835A1/fr
Priority to US10/467,145 priority patent/US20040121961A1/en
Priority to EP02702137A priority patent/EP1365753A2/fr
Priority to AU2002235520A priority patent/AU2002235520A1/en
Priority to JP2002562375A priority patent/JP2004521123A/ja
Publication of WO2002062369A2 publication Critical patent/WO2002062369A2/fr
Anticipated expiration legal-status Critical
Publication of WO2002062369A3 publication Critical patent/WO2002062369A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une méthode destinée à retarder le développement de polypes et de prévention, d'inhibition et de traitement du cancer dans l'intestin d'un sujet consistant en l'administration d'une composition contenant un peptide présentant le domaine actif de l'uroguanyline ou de n'importe quel peptide ou composé agoniste se fixant au récepteur guanylate cyclase GC-C dans l'intestin, en combinaison avec un inhibiteur de cyclooxygénase-2 naturel, dérivé d'un inhibiteur de cyclooxygénase-2 naturel ou un inhibiteur de cyclooxygénase-2 synthétisé par voie chimique, de préférence un inhibiteur de cyclooxygénase-2 sélectif.
PCT/US2002/003201 2001-02-02 2002-02-04 Combinaisons d'uroguanyline et d'inhibiteur de cyclooxygenase-2 pour l'inhibition du cancer de l'intestin Ceased WO2002062369A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002435835A CA2435835A1 (fr) 2001-02-02 2002-02-04 Combinaisons d'uroguanyline et d'inhibiteur de cyclooxygenase-2 pour l'inhibition du cancer de l'intestin
US10/467,145 US20040121961A1 (en) 2002-02-04 2002-02-04 Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
EP02702137A EP1365753A2 (fr) 2001-02-02 2002-02-04 Combinaisons d'uroguanyline et d'inhibiteur de cyclooxygenase-2 pour l'inhibition du cancer de l'intestin
AU2002235520A AU2002235520A1 (en) 2001-02-02 2002-02-04 Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
JP2002562375A JP2004521123A (ja) 2001-02-02 2002-02-04 腸癌阻害のためのウログアニリンおよびシクロオキシゲナーゼ−２阻害薬の組合わせ

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26595501P 2001-02-02 2001-02-02
US60/265,955 2001-02-02

Publications (2)

Publication Number Publication Date
WO2002062369A2 WO2002062369A2 (fr) 2002-08-15
WO2002062369A3 true WO2002062369A3 (fr) 2003-08-28

Family

ID=23012573

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/003201 Ceased WO2002062369A2 (fr) 2001-02-02 2002-02-04 Combinaisons d'uroguanyline et d'inhibiteur de cyclooxygenase-2 pour l'inhibition du cancer de l'intestin

Country Status (5)

Country Link
EP (1) EP1365753A2 (fr)
JP (1) JP2004521123A (fr)
AU (1) AU2002235520A1 (fr)
CA (1) CA2435835A1 (fr)
WO (1) WO2002062369A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8748573B2 (en) 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2330312T5 (es) * 2001-03-29 2014-01-31 Synergy Pharmaceuticals, Inc. Agonistas de receptor de guanilato ciclasa para el tratamiento de la inflamación de tejidos y de la carcionogénesis
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
BR122018074353B8 (pt) * 2003-01-28 2023-05-02 Ironwood Pharmaceuticals Inc composição farmacêutica, polipeptídeo e métodos para a produção dos mesmos
ES2391974T3 (es) 2003-06-13 2012-12-03 Ironwood Pharmaceuticals, Inc. Procedimientos y composiciones para el tratamiento de trastornos gastrointestinales
US7494979B2 (en) 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2559319T3 (es) 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
CA2726913C (fr) 2008-06-04 2020-02-25 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
CA2726917C (fr) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
EP3241839B1 (fr) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
RS60101B1 (sr) 2008-08-15 2020-05-29 Ironwood Pharmaceuticals Inc Formulacije koje sadrže linaklotid za oralnu primenu
EP2341898A2 (fr) * 2008-09-04 2011-07-13 Ironwood Pharmaceuticals, Inc. Formulations solides stables de polypeptides agonistes vis-à-vis du récepteur gc-c se prêtant à une administration par voie orale
WO2010065751A2 (fr) 2008-12-03 2010-06-10 Synergy Pharmaceuticals, Inc. Formulations d'agonistes de guanylate cyclase c et méthode d'utilisation
TR201711271T4 (tr) 2010-02-17 2019-02-21 Ironwood Pharmaceuticals Inc Gastrointestinal Bozukluklar İçin Tedaviler
PL2603232T3 (pl) 2010-08-11 2020-05-18 Ironwood Pharmaceuticals, Inc. Stabilne formulacje linaklotydu
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP6393037B2 (ja) 2010-09-15 2018-09-19 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃアゴニストの製剤および使用方法
HUE032237T2 (en) 2011-08-17 2017-09-28 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders
CA2905438A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047890A1 (fr) * 1997-04-21 1998-10-29 G.D. Searle & Co. Derives de benzopyrannes substitues pour le traitement de l'inflammation
WO2000023433A1 (fr) * 1998-04-17 2000-04-27 G.D. Searle & Co. Analogues substitues de benzopyranne pour le traitement de l'inflammation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047890A1 (fr) * 1997-04-21 1998-10-29 G.D. Searle & Co. Derives de benzopyrannes substitues pour le traitement de l'inflammation
WO2000023433A1 (fr) * 1998-04-17 2000-04-27 G.D. Searle & Co. Analogues substitues de benzopyranne pour le traitement de l'inflammation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FORTE L R: "GUANYLIN REGULATORY PEPTIDES: STRUCTURES, BIOLOGICAL ACTIVITIES MEDIATED BY CYCLIC GMP AND PATHOBIOLOGY", REGULATORY PEPTIDES, ELSEVIER SCIENCE BV, NL, vol. 81, no. 1 - 3, 31 May 1999 (1999-05-31), pages 25 - 39, XP000979549, ISSN: 0167-0115 *
KAWAMORI T ET AL: "CHEMOPREVENTIVE ACTIVITY OF CELECOXIB, A SPECIFIC CYCLOOXYGENASE-2 INHIBITOR, AGAINST COLON CARCINOGENESIS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 58, 1 February 1998 (1998-02-01), pages 409 - 412, XP001145866, ISSN: 0008-5472 *
SHAILUBHAI ET AL: "UROGUANYLIN TREATMENT SUPPRESSES POLYP FORMATION IN THE APCMIN/+ MOUSE AND INDUCES APOPTOSIS IN HUMAN COLON ADENOCARCINOMA CELLS VIA CYCLIC GMP", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, no. 18, 2000, pages 5151 - 5157, XP002159386, ISSN: 0008-5472 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8748573B2 (en) 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide

Also Published As

Publication number Publication date
AU2002235520A1 (en) 2002-08-19
WO2002062369A2 (fr) 2002-08-15
EP1365753A2 (fr) 2003-12-03
CA2435835A1 (fr) 2002-08-15
JP2004521123A (ja) 2004-07-15

Similar Documents

Publication Publication Date Title
WO2002062369A3 (fr) Combinaisons d'uroguanyline et d'inhibiteur de cyclooxygenase-2 pour l'inhibition du cancer de l'intestin
WO2001068092A3 (fr) Inhibiteur de glycogene phosphorylase
WO2002046129A3 (fr) Inhibiteurs de l'histone deacetylase
WO2002047712A3 (fr) Peptide yy et antagonistes de peptides yy destines au traitement des troubles du metabolisme
WO2006071740A3 (fr) Compositions renfermant un modulateur des recepteurs 5ht2c et procedes d'utilisation correspondants
ZA981627B (en) Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
WO2002042295A3 (fr) Agents therapeutiques et procede d'utilisation de ces derniers pour modules l'angiogenese
EP1935427A3 (fr) Utilisations des molécules mutantes solubles CTLA4
WO2005009381A3 (fr) Preparation a liberation immediate de compositions pharmaceutiques labiles en milieu acide
AU2003280087A1 (en) Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
WO2005023179A3 (fr) Methodes combinees de traitement du cancer
EP2261236A3 (fr) Composition destinée a inhiber le proteasome
WO2003097608A3 (fr) Composes opioides et de type opioide et leurs utilisations
HUP0200623A3 (en) 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors and pharmaceutical compositions containing them
ZA200207290B (en) Pharmaceutical compositions of glycogen phosphorylase inhibitors.
AU2003277440A1 (en) Compositions of cyclooxygenase-2 selective inhibitors and nmda receptor antagonists for the treatment or prevention of neuropathic pain
NO20033985L (no) Topisk plasterpreparat som inneholder et forsinket type hypersensitivitets-induksjonsmiddel og fremgangsmåter for å anvende dette
CA2409771A1 (fr) Methode d'utilisation d'antagonistes peptidiques de zonuline pour prevenir ou retarder l'apparition du diabete
IL166621A0 (en) Polymorph of n-methyl-n-(3-ä-3-Ä2-thienylcarbonylÜ-pyrazol-Ä1,5-alphaÜpyrimidin-7-ylüacetamide and pharmaceutical compositions containing the same
WO1999065513A3 (fr) COMPOSITIONS PHARMACEUTIQUES POUR LE TRAITEMENT DE TROUBLES ASSOCIES AU $i(HELICOBACTER PYLORI)
WO2002016312A3 (fr) Nouveaux composes inhibant l'activite du facteur xa
ZA200403690B (en) Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (TFPI).
NO2010004I1 (no) 0,02 mg etinylostradiol (som betadexclathrat) og 3mg drospirenon
AU2002223633A1 (en) Use of stimulators of soluble guanylate cyclase for treating osteoporosis
BG105197A (en) Polymorph form of a medicament

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002702137

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2435835

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002562375

Country of ref document: JP

Ref document number: 10467145

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002702137

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002702137

Country of ref document: EP